A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
- 21 February 2022
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 38 (5) , 661-671
Abstract
To evaluate the effectiveness of vortioxetine in major depressive disorder (MDD) when used as a first-line versus second-line treatment or later. This was a post-hoc analysis of three 3-month non-interventional, prospective studies of vortioxetine in MDD – REVIDA (Malaysia, Philippines, Singapore, Thailand), PREVIDA (Pakistan) and TREVIDA (Taiwan). Improvements in depressive symptoms (PHQ-9, CGI-S), cognitive function (PDQ-D) and work productivity (WPAI) were compared between studies, and in a pooled analysis of patients using vortioxetine as first line versus second-line treatment or later. Safety was compared between studies. Overall, 798 patients were analyzed (PREVIDA =425, REVIDA =130, TREVIDA =243). Most patients in PREVIDA (60.5%)/REVIDA (57.4%) used vortioxetine as first-line treatment versus TREVIDA (21.8%). Generally, greater improvements from baseline were observed across outcome measures in PREVIDA/REVIDA versus TREVIDA (Month 3, p < 0.0001). Vortioxetine as first-line treatment was associated with greater improvements in depression severity, cognition, functioning outcomes compared to second-line or later users (PHQ-9: -16.1 [6.4] vs -10.8 [8.9]; CGI-S: -2.7 [1.1] vs -2.0 [1.4]; PDQ-D: -29.5 [17.7] vs -18.5 [21.4]; p < 0.0001 at Month 3) as well as greater response (PHQ-9: 88.6% vs 61.5%; p < 0.0001) and remission rates (PHQ-9: 75.4% vs 47.7%; p < 0.0001). No new adverse events were reported outside of the product label. In the Asian real-world setting, vortioxetine showed greater improvements in depressive and cognitive symptoms, work functioning, and response and remission rates when used as first-line versus second-line treatment or later. Vortioxetine was well-tolerated irrespective of the study population across Asia.Keywords
This publication has 43 references indexed in Scilit:
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disordersThe World Journal of Biological Psychiatry, 2013
- Use of antidepressants in the treatment of depression in Asia: Guidelines, clinical evidence, and experience revisitedAsia-Pacific Psychiatry, 2013
- A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorderInternational Clinical Psychopharmacology, 2012
- Low prevalence of major depressive disorder in Taiwanese adults: possible explanations and implicationsPsychological Medicine, 2011
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant MedicationJournal of Clinical Psychopharmacology, 2011
- Long‐term social functioning after depression treated by psychiatrists: a reviewBipolar Disorders, 2007
- The PHQ-9Journal of General Internal Medicine, 2001
- Cost-effectiveness of antidepressant treatment reassessedThe British Journal of Psychiatry, 1997
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993